PERSPECTA

News from every angle

← Back to headlines

argenx announces positive results from ALKIVIA trial for autoimmune myositis

argenx has reported positive topline results from its Phase 3 ALKIVIA trial, evaluating efgartigimod for the treatment of autoimmune myositis.

17 Aug, 05:00 — 17 Aug, 05:00
PostShare

Sources

Showing 1 of 1 sources
taiwan-newsMostly Factual18d ago

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Taiwan News

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis  Taiwan News

Read full article →

Related Stories

Salmonella outbreak from pumpkin seeds infects 81 in France

1h ago

Pediatricians Issue Health Guidelines for Parents Ahead of New School Year

2h ago

Genetically Modified Pig Kidney Sets New Survival Record in US Patient

4h ago

West Nile Virus Cases Confirmed in Netherlands and Major US City

5h ago